Research

LIke ThisLIke ThisLIke This

Robin Kleiman, PhD

Robin Kleiman
Research Center:
Translational Neuroscience CenterF.M. Kirby Neurobiology Center
Program:
Neurobiology Program
Department:
Neurology Research
Hospital Title:
Research Associate
Academic Title:
Assistant Professor of Neurology, Harvard Medical School
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Dr. Kleiman has contributed to the discovery and development of multiple novel clinical candidates and has worked at companies that span the big pharma, start-up and biotech industries. Her background includes leading discovery programs, overseeing external collaborations, consulting, and management experience at several biotech companies and Pfizer. She was one of several founding members of the Pfizer Neuroscience Phosphodiesterase platform team that produced multiple clinical candidate molecules, 3 first-in-human clinical trials for distinct and completely novel mechanisms followed by 2 proof-of-concept clinical trials. She led an interdisciplinary effort to use human risk gene biology to develop a strategy for new target identification and validation that will yield novel therapeutics to treat psychiatric disorders. More recently she was the Director of Research at Selventa and oversaw a portfolio of projects aimed at identification of personalized biomarkers of diseases or the response of individual patients to specific therapies. Dr. Kleiman joined the Translational Neuroscience Center (TNC) leadership team and faculty at Boston’s Children’s Hospital in August of 2013 as the Head of Preclinical Research to provide drug discovery expertise to the members of the TNC community, develop a robust portfolio of translational research projects and foster more in-depth collaboration with industry and disease-based foundations to develop novel therapies to improve the lives of pediatric and adolescent patients.  Dr. Kleiman is Co-Director of the TNC’s Human Neuron Core which develops patient-derived neuronal models of disease in a tissue culture dish for drug screening.

About Robin Kleiman

Robin Kleiman is a research scientist specializing in neuroscience and systems biology. She has 14 years of experience in drug discovery which includes new target identification and validation, biological pathway mining, biomarker discovery and drug development. She holds a B.S. degree in Zoology from University of Vermont, a Ph.D. in Neuroscience from University of Virginia, and completed post-doctoral work at the University of California, San Francisco. 

Publications

Publications powered by Harvard Catalyst Profiles
  1. Smedemark-Margulies N, Brownstein CA, Vargas S, Tembulkar SK, Towne MC, Shi J, Gonzalez-Cuevas E, Liu KX, Bilguvar K, Kleiman RJ, Han MJ, Torres A, Berry GT, Yu TW, Beggs AH, Agrawal PB, Gonzalez-Heydrich J. A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia. Cold Spring Harb Mol Case Stud. 2016 Sep; 2(5):a001008.
  2. Kleiman RJ, Ehlers MD. Data gaps limit the translational potential of preclinical research. Sci Transl Med. 2016 Jan 6; 8(320):320ps1.
  3. Brownstein CA, Kleiman RJ, Engle EC, Towne MC, D'Angelo EJ, Yu TW, Beggs AH, Picker J, Fogler JM, Carroll D, Schmitt RC, Wolff RR, Shen Y, Lip V, Bilguvar K, Kim A, Tembulkar S, O'Donnell K, Gonzalez-Heydrich J. Overlapping 16p13.11 deletion and gain of copies variations associated with childhood onset psychosis include genes with mechanistic implications for autism associated pathways: Two case reports. Am J Med Genet A. 2016 May; 170A(5):1165-73.
LIke ThisLIke ThisLIke This

RELATED RESEARCH CENTER

Translational Neuroscience Center

Learn more

RELATED RESEARCH CENTER

F.M. Kirby Neurobiology Center

The F.M. Kirby Neurobiology Center, together with the Neurobiology Program at Boston Children’s Hospital, is the largest basic neuroscience research enterprise at a U.S. hospital. It incorporates basic and translational neuroscience research, focusing primarily on developmental neurobiology.

Learn more
Close